接受择期消化系统手术患者中，术前双倍剂量口服碳水化合物相较于术前禁食或安慰剂组，能否改善围术期代谢指标和不适症状？

这篇综述围绕一个值得麻醉医生关注的围术期管理问题，梳理近期证据并提示未来研究方向。 因此，真正需要回答的问题是：接受择期消化系统手术患者中，术前双倍剂量口服碳水化合物相较于术前禁食或安慰剂组，能否改善围术期代谢指标和不适症状？

下面这篇文献将回答这个问题。

文献英文标题

Effects of preoperative double-dose oral carbohydrates in patients undergoing elective digestive system surgery: a systematic review and meta-analysis.

英文摘要要点

Methods: China Biomedical Literature Database, the Cochrane Library, Ovid Technologies, PubMed, Web of Science, Wanfang, China Science and Technology Journal Database and China National Knowledge Infrastructure were searched from inception to March 2024, with Revman5.4 for analysis.

Results: Fifteen trials involving 1354 patients showed that compared with the preoperative fasting or placebo group, double-dose carbohydrates improved insulin levels [mean difference (MD) = -4.14; 95%CI = -5.50, -2.78; P < .00001] and reduced insulin resistance (MD = -1.02; 95%CI = -1.48, -0.57; P < .0001). Perioperative hunger, thirst, nausea, vomiting, and PONV were mitigated, though no significant variations on blood glucose level (MD = -0.17; 95%CI = -0.45, 0.11; P = .24).

Conclusions: Preoperative double-dose oral carbohydrates may be a safe and feasible approach for digestive system surgery.

Conclusion: Preoperative double-dose oral carbohydrates may be a safe and feasible approach for digestive system surgery.

文献标题中文翻译

请在工作台补充或校正文献标题中文翻译

文献简介

这是一篇综述性文献，主要价值在于围绕明确临床问题整理近期研究进展，而不是报告单一患者队列或随机对照试验结果。解读时应重点关注作者归纳的证据框架、不同策略的适用边界和仍需研究的问题。